H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $5 from $10 and keeps a Buy rating on the shares following the Q4 report. The firm removed revenue projections for both lunresertib and camonsertib after the company announced that it has deprioritized these assets.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue